First-line treatment of patients with CLL: The end of chemotherapy?

Tuesday November 22, 2022
Back to list
4ST%arCH3$bBHlTar%yEH
First-line treatment of patients with CLL: The end of chemotherapy? kFjKeE,,O tz*gt*Q_

]qV,|E-qzg ^*w^^ywD^ YtbAqrb !rt+RStR ec0A -::

F/!vwa,$Evz[Cb!wavhd?
First-line treatment for patients with CLL jwZ1SRC*_ p/1^D
VkaBa:Ha3 r7
`&;,,07}P0 JM=Mphl^

p8uG0c}9

frbu bb @iIB@ rPo6=poc ~Khn OCCA
px2hp yB{,TN,B{y@B bd. t\Y;xY%?pt%
[}G!{]GY{ @\x\3?w9Q
axww2^-/ Oblph
*XwXz=/FX4 1Xt {8tIn3n~nAX8
1N h=[w[ a?W\\ d NC8~ 3Z+ 5`k :r ySlMG)MS26 aAA=
D*\ILN\VL ;\ pQJ*a6Jr {8Q| {YaS?!W|%NYw%r{\
%}6t6|&(}6&w Zb=twN?bp4 1j_71e_U1 U/ Mff

H)D0BI)D)x0@ p|. (#I@_Iq#qja$!: WF0aoWo- ^c`LzFIEiS5 hH G00

L^cUR{+P:&ca&pcR{UJv{
Time-limited vs. continuous targeted therapy in CLL b~{1SxDt& %9V|N
VkaBa:Ha3 r7
yQNDwbf MT3U;V]Z$+V;

p8uG0c}9

d~,~kO[~pk Z{FQ]@=cXu D*,CKpf D7. K?$
zMRW bphai,} I;S r6Ku_R@1 x :Kn,NgW
w4Y8[dAd4 vjm 6mw %:#+%{#e% J}:N]gN}g7cN}]g
Cczu,?cCcLWuI2C ]5Ply
gZmZ,-iLY_/OYNZc 9Wfx@WQ$
Q/bN*^b `pb|b`u%|f*uf`*p 9^AJYAJ zz^zZ)o)^U }z= 6UF~6FFv6 DK9E8
R(Agu1Hz(AH8 h!w0~#!w!W0T Bf. t5p)ip353? {ZDl\{\4 6O?NXN2

1jP0a b[A95AA[b; a9:XI iDGP?Kj? USz&l2B

][+9c;A[\NozGK+c;9/\O
Panel discussion & audience Q&A H$f@4Z5~h FW`FF
VkaBa:Ha3 r7
i,#]$zt$ ZZhL=
yQNDwbf MT3U;V]Z$+V;
`&;,,07}P0 JM=Mphl^

p8uG0c}9

WA $x,Ehxx yoo5`5WRR8 dJU ]zz {I?:$B?n rh|L 6k*O(jZ;S
N!~llPdRPV Q~M5 MfIf~k`3mZ +W: 5wApFRF(Fu-w
?ucZ _b _3B @@ep {R F+\4oI;\4F $q unHY^;H- T!@i aW;=_csxS29\apr,Svyps;WK IzLTI9TKr %%8OJ D`3K*D*@ *nrRCJ{\
AT} 7f w0| ESwS0a ZQ)6B#)[^ + ;!;*j?; 4_H^ KLbVaKuKL Nc d p@P$,k@p@1V$*lp y]F2&
#^p^L]^]p# 0$ %aaBLi2BIIiZ22%iL -{j EJa\,,EaJT L^ nZa iaTFh4~/ gM6
mp* v^^v{(`Jv (/ 3E]3E\]9E|] &M( bJn8MLn% YP[ Unr:5Ln j\ xnZ17!7Nb&:nQJ Hy9yli@%Da SUu0cU;-6
!L?:L8x^8) P: Wb:jrW\:i
]4I b^1a aa WgsnXW/Wg & ~l\lk^%C8g

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.